A Novel Bifunctional Phospholipase C That Is Regulated by Galpha 12 and Stimulates the Ras/Mitogen-activated Protein Kinase Pathway*

Isabel LopezDagger , Eric C. MakDagger , Jirong DingDagger , Heidi E. Hamm§, and Jon W. LomasneyDagger §||

From the  Veterans Affairs Chicago Health Care System-Lakeside Division and the Dagger  Department of Pathology and Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, Illinois 60611 and the § Institute of Neuroscience and Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, Illinois 60611

Received for publication, September 5, 2000, and in revised form, October 3, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Three families of phospholipase C (PI-PLCbeta , gamma , and delta ) are known to catalyze the hydrolysis of polyphosphoinositides such as phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol 1,4,5 trisphosphate and diacylglycerol, leading to a cascade of intracellular responses that result in cell growth, cell differentiation, and gene expression. Here we describe the founding member of a novel, structurally distinct fourth family of PI-PLC. PLCepsilon not only contains conserved catalytic (X and Y) and regulatory domains (C2) common to other eukaryotic PLCs, but also contains two Ras-associating (RA) domains and a Ras guanine nucleotide exchange factor (RasGEF) motif. PLCepsilon hydrolyzes PIP2, and this activity is stimulated selectively by a constitutively active form of the heterotrimeric G protein Galpha 12. PLCepsilon and a mutant (H1144L) incapable of hydrolyzing phosphoinositides promote formation of GTP-Ras. Thus PLCepsilon is a RasGEF. PLCepsilon , the mutant H1144L, and the isolated GEF domain activate the mitogen-activated protein kinase pathway in a manner dependent on Ras but independent of PIP2 hydrolysis. Our findings demonstrate that PLCepsilon is a novel bifunctional enzyme that is regulated by the heterotrimeric G protein Galpha 12 and activates the small G protein Ras/mitogen-activated protein kinase signaling pathway.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Many hormones, neurotransmitters, and growth factors elicit intracellular responses by activating a family of inositol phospholipid-specific phospholipase C (PLC)1 isozymes (1, 2). There are three established families of PLC termed beta  (~150 kDa), gamma  (~145 kDa), and delta  (~ 85 kDa) (3). All three families of the PI-PLC family are able to recognize phosphatidylinositol (PI), phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-bisphosphate (PIP2) and to carry out the Ca2+-dependent hydrolysis of these inositol phospholipids. It is presumed that the primary substrate for hydrolysis is PIP2, which yields the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases intracellular Ca2+ from the endoplasmic reticulum via interaction with a specific receptor located on the surface of the endoplasmic reticulum. DAG, as well as increased intracellular Ca2+, activate protein kinase C leading to a cascade of intracellular events including regulation of cellular growth, smooth muscle contraction, and cardiac hypertrophy (2).

The mode of regulation differs considerably for members of the different isoform families. The beta  isoforms are regulated by large heterotrimeric G proteins. After activation by agonists such as epinephrine, alpha 1 adrenergic receptors are able to couple to Galpha subunits from the Gq/G11 family and stimulate hydrolysis of phosphatidyl inositol lipids via PLC beta  isoforms. For some beta  isoforms, Gq alone is sufficient for activation, whereas for others the coordinated action of both Gq and beta gamma is necessary. The gamma  isoforms of PLC contain SH2 and SH3 domains; hence, they are activated by both receptor and nonreceptor tyrosine kinases. Until recently, the mode of regulation of the delta  class was unknown. Work from our laboratory and that of others has determined that this class is regulated in vitro by lipid ligands and ionized free calcium (regulation by calcium via C2 domain is described by Lomasney et al.)2 (4-7).

Activation of G protein-coupled receptors modulates various aspects of cellular growth and proliferation, processes that are primarily controlled by small Ras-related G proteins and their downstream effector, the mitogen-activated protein (MAP) kinases (8, 9). There appear to be multiple mechanisms involving heterotrimeric Galpha and beta gamma subunits by which G protein-coupled receptors regulate small monomeric G protein function (10). Gbeta gamma subunits can induce phosphorylation of the Shc adapter protein leading to association with the Grb2 docking protein and eventual stimulation of Ras guanine nucleotide exchange activity (11). Galpha i and Galpha o subunits can lead to activation of MAP kinase via a protein kinase C-dependent pathway (12). Recently, a novel molecule, p115 RhoGEF, has been identified that serves as a direct link between the heterotrimeric Galpha subunit Galpha 13 and the small G protein Rho (13, 14). Galpha 13 stimulates the nucleotide exchange activity of p115 RhoGEF for Rho. p115 RhoGEF also serves as a GTPase-activating protein for Galpha 13 and Galpha 12. This is the first example of a protein that is able to directly link large and small G protein pathways. In this report we identify a novel fourth class of PI-PLC that we designate PLCepsilon and demonstrate that PLCepsilon interacts with large and small G proteins, although it is very different from p115 RhoGEF.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Cloning of hPLCepsilon cDNA-- A computer search of the human GenBankTM expressed sequence tag (EST) data base was conducted using three relatively short amino acid sequences from the conserved X and Y domains of the mammalian PLCs. An EST clone, zb59f12.s1, showed a high degree of homology and contained a putative open reading frame. Screening of a human placental cDNA library with the EST cDNA probe yielded a larger (3.0 kilobases) but still incomplete cDNA fragment. The full-length PLCepsilon cDNA was generated by 5' rapid amplification of cDNA ends utilizing the Marathon cDNA amplification kit (CLONTECH). The cDNA was reverse transcribed from poly(A)+ mRNA obtained from human heart (CLONTECH), using the cDNA synthesis primer provided with the kit. The PCR amplification was carried out using adaptor primer 1 (5'-CCATCCTAATACGACTCACTATAGGGC-3') and a gene specific reverse primer, 5'-TCCACCGTCTGCCACCAAACAACTCCACA-3'. The first round PCR was performed according to the recommendations of the manufacturer of 94 °C for 1 min, five cycles at 94 °C for 5 s and 72 °C for 4 min, another five cycles at 94 °C for 5 s and 70 °C for 4 min, followed by 25 cycles at 94 °C for 5 s and 68 °C for 4 min. The second round of PCR was performed under the same conditions using a 1:200 dilution of the first round PCR amplification mixture as the template, adaptor primer 2 (5'-ACTCACTATAGGGCTCGAGCGGC-3') and a nested gene-specific primer (5'-AGCAGCGGGCAGAGAGGTGTGTGTCC-3'). Southern blot analysis using an end-labeled internal oligonucleotide (5'-TGTCAACAGCATCTTTCAGGTCATCC-3') 5' from the PCR primers confirmed that the PCR product contained the expected sequence. The PCR product was subcloned into the PCR2.1 TA cloning vector (InVitrogen) according to the recommendations of the manufacturer. Positive clones were identified by hybridizing filter lifts with the same labeled oligonucleotide that was described for the Southern blots. Clones containing the expected size DNA fragment were then sequenced along both strands using the Taq dye terminator method at the University of Georgia Molecular Genetics Facility, Department of Genetics, using Applied Biosystems 373 and 377 automatic sequencers. The entire hPLCepsilon cDNA was obtained from heart cDNA by PCR using the following primers: 5'-ATGGTTTCAGAAGGAAGTGCAGCAGGAA-3' (sense) and 5'- TCACTGTCGGTAATCCATTGTGTCACTGG-3' (antisense). The PLCepsilon cDNA was subcloned in-frame into pBluescript KS+. The sequence of the inserted DNA was determined as previously mentioned.

Creation of the Phosphodiesterase-deficient Mutant hPLCepsilon H1144L-- The phosphodiesterase-deficient mutant of hPLCepsilon , PLCepsilon H1144L, was generated by changing the histidine residue at position 1144 to leucine using the QuickChange Kit (Stratagene). Briefly, the fragment of PLCepsilon containing the mutation was amplified with Pfu Turbo Polymerase (Stratagene) using sense (5'-GCTTGACGGCGCCTCCGG-3') and antisense (5'-CTACCCTACGGGTAGTAAATAGAACCTGTATGCGACTGTTGGTTC-3') primers containing the mutation changing the histidine (CAT) to a leucine (CTT). The PCR was performed according to the recommendations of the manufacturer of 95 °C for 30 s, 12 cycles at 95 °C for 30 s, 1 min at 55 °C and 4 min at 68 °C. A second fragment overlapping the first was amplified using the sense primer, 5'-GATGGGATGCCCATCATTTATCTTGGACATACGCTGACAACCAAG-3' and an antisense primer (5'-AACGGGGAGGGGGCACGG-3') corresponding to pcDNA3 vector, 3' from the multiple cloning site of the vector. The PCR was also performed according to the recommendations of the manufacturer of 95 °C for 30 s, 12 cycles at 95 °C for 30 s, 1 min at 55 °C, and 6 min at 68 °C. The overlapping products were then used to amplify the entire PLCepsilon cDNA from nucleotide1278-6507 using the sense primer 5'-GCTTGACGGCGCCTCCGG-3' and the antisense primer corresponding to the vector just 3' of the multiple cloning site. The PCR conditions were 95 °C for 30 s, 12 cycles at 95 °C for 30 s, 55 °C for 1 min, and 10 min at 68 °C. After ligation and plasmid preparation, the mutant insert was digested with SacII and XbaI. The mutated fragment was gel purified using the QIAquick gel extraction kit (Qiagen) and ligated into pcDNA3 in place of the wild type fragment. The sequence was then verified for the presence of the H1144L mutation and the absence of any additional mutations.

Northern Blot Analysis-- Human multiple-tissue Northern blot I and blot IV membranes (CLONTECH) containing approximately 2 mg of poly(A)+ RNA/lane were probed with full-length cDNA of hPLCepsilon or beta -actin according to the manufacturer's instructions. Briefly, 30 ng of hPLCepsilon or beta -actin were random-primed with [alpha -32P]dCTP (<6000 Ci/mmol; PerkinElmer Life Sciences) using the Prime-It II random primer labeling kit (Stratagene). Unincorporated radionucleotide was removed from the probe by using Bio-Spin 30 chromatography columns (Bio-Rad). The radiolabeled probes were then denatured by boiling for 5 min and placed on ice. Membranes were prehybridized in 15 ml of Express hyb solution (CLONTECH) with continuous shaking at 68 °C for 1 h. The prehybridization buffer was replaced with 10 ml of fresh ExpressHyb solution containing the radiolabeled probe. After a 1-h incubation at 68 °C with continuous shaking, the blots were quickly rinsed several times with 2× SSC, 0.05% SDS at room temperature and then washed twice for 10 min at room temperature in the same buffer. This was followed by two 20-min washes with fresh 0.1× SSC, 0.1% SDS at 50 °C and continuous shaking. The blots were then wrapped in plastic wrap and exposed to HyperFilm MP x-ray film (Amersham Pharmacia Biotech) at -80 °C with two intensifying screens for 4-24 h before developing the film. Blots exposed to multiple probes were stripped of the first probe as suggested by the manufacturer's protocols.

Transient Transfection of TSA201 Cells-- The hPLCepsilon cDNA was subcloned in-frame into the unique HindIII and NotI sites of the mammalian expression vector pcDNA3 (InVitrogen) downstream of the cytomegalovirus promotor. A Kozak consensus sequence (TAAT) and a Myc tag (5'-ATGGAGCAGAAGCTGATCAGCGAGGAGGACCTG-3') were incorporated in frame before the start codon. Plasmids were purified for transfection using Qiagen kits. TSA201 cells were cultured in complete Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing glutamine, high glucose, 10% fetal bovine serum (Life Technologies, Inc.), and 50 mg/ml gentamicin (Life Technologies, Inc.) at 37 °C in a humidified 5% CO2 incubator. The cells were transfected with Myc-hPLCepsilon or pcDNA3 empty vector using LipofectAMINE (Life Technologies, Inc.) according to manufacturer's instructions with slight modifications. Cells were harvested 48 h after transfection.

Immunoblotting-- Samples were subjected to 6% or 15% SDS-polyacrylamide gel electrophoresis and were electrophoretically transferred to nitrocellulose as described previously (15). hPLCepsilon was detected by Western blot analysis using a primary anti-Myc tag antibody (InVitrogen). Galpha * subunits were detected using specific anti-Galpha antibodies. Alkaline phosphatase or horseradish peroxidase-conjugated secondary antibody (IgG) was used for detection.

PLC Activity in TSA201 Cells-- TSA201 cells were transfected with either pcDNA3 vector (control), hPLCepsilon , hPLCepsilon H1144L, Galpha s*, Galpha i*, Galpha 12*, Galpha 13* cDNA, or Ras (2 mg/35-mm plate) alone or in combination using LipofectAMINE (Life Technologies, Inc). To maintain uniform amount of transfected DNA, empty vector was added to the transfection mixture when necessary. The cells were labeled with [3H]myo-inositol (PerkinElmer Life Sciences) for 24 h and harvested 48 h after transfection. The amount of inositol phosphates (inositol 1-phosphate, inositol 1,4-bisphosphate, and IP3) was determined using anion exchange chromatography (16). The percentage of PI hydrolyzed is expressed as the total inositol phosphates formed relative to the amount of [3H]myo-inositol incorporated into the phospholipid pool.

Cell Free Assays-- TSA201 cells were transfected with either vector (control) or hPLCepsilon cDNA (12 mg DNA/100-mm plate). Cells were harvested 48 h after transfection and homogenized in ice-cold lysis buffer (50 mM Tris, pH 7.5, 30 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 2 mM leupeptin, 1 mM aprotinin, and 1 mM pepstatin). Cytosolic and particulate fractions were isolated as described previously (15). Cytosolic and membrane fractions were then assayed for PLC activity using a vesicle assay previously described with slight modification (17). Substrate was provided as mixed phospholipid vesicles containing phosphotidylinositol-4,5-bis phosphate, PIP2 (28 mM), and phosphatidylethanolamine (280 mM) in a ratio of 1:10 with 25,000- 35,000 cpm of [3H]PIP2/assay. PLC assays were performed at 37 °C for varying time periods in a mixture (70 ml) containing 50 mM HEPES, pH 7.3, 3 mM EGTA, 0.2 mM EDTA, 1 mM MgCl2, 20 mM NaCl, 30 mM KCl, 4 mM dithiothreitol, 0.1 mg/ml acetylated bovine albumin, 1.6 mM sodium deoxycholate, and 1 mM CaCl2 The reactions were started by addition of the transfected cell membranes and terminated by adding 350 µl of chloroform/methanol/concentrated HCl (500:500:3, v/v/v). The samples were vortexed, and 100 µl of 1 M HCl containing 5 mM EGTA was added. Phases were separated by centrifugation and assayed for radioactivity by liquid scintillation counting.

MAP Kinase Assay-- TSA201 cells were co-transfected (12 mg DNA/100 mm plate) with vector, hPLCepsilon , hPLCepsilon H1144L, or RasGRF2 in combination with HA-tagged MAP kinase (2 mg). 24 h after transfection the cells were serum starved over night. Cells were lysed 48 h after transfection as described previously with slight modifications (18). Briefly, cells were washed twice with ice-cold phosphate-buffered saline (Life Technologies, Inc.) and lysed by addition of one volume 10× MAP kinase lysis buffer (5.5% Triton X-100, 0.2 mM phenylmethanesulphonyl fluoride, 0.7 mg/ml pepstatin A, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 20 mM sodium orthovanadate, and 20 mM sodium pyrophosphate) to 10 volumes phosphate-buffered saline. The cells were incubated for 10 min at 4 °C and centrifuged at 4 °C for 15 min at 10,000 × g. Activated MAP kinase was immunoprecipitated by incubating the cells for 2 h with anti-HA antibodies (Upstate Biotechnology Inc., 0.4 mg/ml). At the end of the incubation period precleared protein A beads (50% slurry) were added, and the samples were rotated 2 h at 4 °C. The ability of MAP kinase to phosphorylate myelin basic protein was measured following the manufacturer's protocol (Upstate Biotechnology Inc.). Protein samples were separated on 6% (PLCepsilon and H1144L) and 15% SDS-polyacrylamide gel and subsequently transferred to nitrocellulose at room temperature for 1 or 2 h at 5 or 15 V, respectively, using a semidry transfer cell (Bio-Rad). The HA monoclonal antibody (clone 12CA5; Roche Molecular Biochemicals) was used to detect HA-MAP kinase, anti-FLAG M2 antibody (Sigma) was used to detect FLAG-tagged RasGRF2, and anti-Myc antibody (InVitrogen) was used to detect hPLCepsilon and the H1144L mutant. The horseradish peroxidase-coupled goat anti-mouse antibody (1:2,000; Sigma) was used as the secondary antibody. The blots were developed by ECL (Amersham Pharmacia Biotech).

Ras Pull-down Assays-- TSA201 cells were transiently co-transfected as previously mentioned with either control plasmid (pcDNA3), hPLCepsilon , hPLCepsilon H1144L, or RasGRF2 and Ha-Ras. The cells were serum-starved for 24 h. 48 h after transfection the cells from a 10-cm dish were lysed and scraped in 1 ml of RIPA buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 0.1 mM aprotinin, 1 mM leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Lysates were centrifuged at 14,000 rpm for 8 min at 4 °C to remove nuclei. The desired amount of bacterial lysate containing the expressed GST-Ras-binding domain (GST-RBD) of Raf1 (prepared as described by de Rooij and Bos (19)) was thawed on ice and incubated with glutathione-agarose beads at 4 °C for 1 h. The beads were isolated by centrifugation and washed three times with RIPA buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM pepstatin, and 1 mM phenylmethylsulfonyl fluoride at 4 °C. Cell lysates were added to GST-RBD precoupled to glutathione-agarose beads and incubated at 4 °C for 1 h. Beads were collected by centrifugation, washed three times with RIPA buffer, and resuspended in SDS sample buffer. GTP bound Ras was identified by precipitation with GST-Raf RBD followed by immunoblotting as described previously by de Rooij and Bos (19). The protein samples were separated on 6% (PLCepsilon and H1144L) and 15% SDS-polyacrylamide gel and subsequently transferred to nitrocellulose at room temperature for 1 h at 5 V using a semidry transfer cell (Bio-Rad). The monoclonal antibody Y13-259 (1:500, Transduction Labs) was used to detect Ras and anti-Myc tag antibody was used to detect hPLCepsilon and the H1144L mutant. The horseradish peroxidase-coupled goat anti-mouse antibody (1:2,000, Sigma) was used as the secondary antibody. The blot was developed by ECL (Amersham Pharmacia Biotech).


    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Isolation of the cDNA Encoding Human PLCepsilon , Determination of Expression in Human Tissues, and Identification of Structural Features-- X and Y domains are regions of ~170 and ~260 amino acids, respectively, which share 60% to 40% amino acid identity among all PLC isoforms. The X and Y domains are necessary for phosphodiesterase activity of PLC. We selected three relatively short amino acid sequences from the conserved X and Y domains to use in a BLAST search. The Basic Local Alignment Search Tool (BLAST) is an extremely powerful tool that allows one to simultaneously search multiple nucleotide sequence data bases. Using the BLAST server at the National Center for Biotechnology Information, we were able to identify an EST clone that partially encoded for a novel PLC isoform. Using the EST cDNA as a probe, a human placental cDNA library was screened yielding a larger but still incomplete cDNA. A full-length cDNA clone was ultimately generated with 5' rapid amplification of cDNA ends PCR using human heart mRNA as template that we termed PLCepsilon . The full-length cDNA (Fig. 1A) possesses an open reading frame of 6.05 kilobases encoding a 1994-amino acid protein with a calculated molecular mass of 230,000, making this the largest PLC isolated to date. The next largest would be a member of the beta  family at ~1300 amino acids and ~150 kDa. Hybridization of human multiple tissue Northern blots with PLCepsilon cDNA revealed a ~7.5-kilobase message corresponding to PLCepsilon expressed in a wide variety of tissues including brain, lung, kidney, testis, and colon with highest expression detected in the heart (Fig. 2). An additional transcript of larger size (~9.5 kilobases) could be observed in most tissues, suggesting the possibility of an alternatively spliced form of PLCepsilon or differential polyadenylation. Results from Southern blotting indicate that isoforms likely do not exist (data not shown).



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Structure and comparison of PLCepsilon . A, Full-length amino acid sequence of human PLCepsilon . Highlighted residues indicate the identified protein domains. X and Y, X and Y domains, catalytic core regions of PI-PLCs; PH, pleckstrin homology domains; C2, calcium-regulated lipid binding domain; RA, Ras-associating domain. B, schematic comparison drawn to scale of the PLC family functional domains. X and Y, X and Y domains, catalytic core regions; PH, pleckstrin homology domains; C2, calcium-regulated lipid binding domain; SH, Src homology domain; RA, Ras-associating domain. C, evolutionary comparison depicting the relationships among all known isoforms of eukaryotic PLC and PLCepsilon . Clustal X was used to generate alignments of the primary structures which were then displayed with TreeView. The scale bar is used to quantitate branch lengths. A scale of "0.1" means 0.1 amino acid substitutions/residue.



View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Tissue distribution of hPLCepsilon mRNA. Multiple human tissue Northern blots were analyzed as described under "Experimental Procedures." Each lane contains approximately 2 mg of poly(A)+ RNA. Blots were hybridized with the full-length cDNA or beta -actin probe. The hybridized membrane was exposed to x-ray film for 24 h. kb, kilobases.

Structural analysis reveals that PLCepsilon contains the conserved catalytic X and Y domains, thus identifying this isoform conclusively as a Pl-PLC (Fig. 1B). Like members of the three other PLC families, PLCepsilon also contains the regulatory C2 domain. Unlike other eukaryotic PLCs, PLCepsilon appears not to contain a pleckstrin homology domain. A phylogenetic comparison of all known mammalian PLC isoforms (Fig. 1C) demonstrates that PLCepsilon shares little homology with other PLC families (beta , gamma , and delta ) and therefore constitutes a distinct family of PLCs. PLCepsilon is most similar to PLC210, a largely uncharacterized isoform from the nematode Caenorhabditis elegans (20). PLC210 was first identified by open reading frame prediction of genomic sequences generated from the C. elegans genome sequencing project. Although there are significant similarities, human PLCepsilon also differs considerably from PLC210. PLCepsilon is considerably larger than PLC210 (~200 amino acids) and differs extensively in the primary structure of the C terminus and portions of the N terminus. We predict that the C terminus of PLCepsilon will mediate protein-protein interactions that are completely different from those of PLC210. Interestingly, both PLCepsilon and PLC210 share structural domains that are not present in any other PLC, further suggesting the existence of a novel PLC family. Both PLCs contain a Ras binding motif denoted as the RA domain (21). Although the functional role of RA domains is presently unknown, a recent report has demonstrated that PLC210 binds to Ha-Ras via this domain, suggesting a possible role of this isoform in Ras signaling (20). A number of other RA domain-containing proteins such as RalGDS and RGL are also known to bind to Ras (21). PLCepsilon has two RA domains at the C terminus (amino acids 1688-1792 and 1813-1916), suggesting that it might interact with the effector region of Ras (Fig. 1B). PLCepsilon also contains domains in the N terminus, which suggests that it may interact with small G proteins of the Ras superfamily. Very significant homology (p < 0.00001) is found with aimless RasGEF from Dictyostelium, CDC25 RasGEF from yeast (both Candida albicans and Saccharomyces cerevisiae), human RasGEF homolog Sos1, human RasGEF H-GRF55, and son-of-sevenless RasGEF from mouse. The area of homology is encompassed by the RasGEF catalytic domain signature (G/A/P)CVP(F/Y)X4(L/I/M/F/Y)X(D/N)(L/I/V/M) PROSITE121 (22). No other eukaryotic PLC contains these Ras binding motifs. This strongly suggests that PLCepsilon activates Ras signal transduction pathways.

Expression of PLCepsilon in TSA201 Cells and Characterization of Polyphosphoinositide Hydrolysis-- Western blot analysis of cell lysates from TSA201 cells (a clone of human embryonic kidney 293 cells stably expressing simian virus 40 large T antigen) revealed the presence of a single protein of approximately 230 kDa from cells transfected with PLCepsilon cDNA inserted into the mammalian expression vector pcDNA3 but not from control cells (Fig. 3A) (23). The observed apparent molecular mass of 230 kDa is consistent with the predicted molecular mass of PLCepsilon . Extensive PLCepsilon immunoreactivity resides in the particulate fraction of transfected TSA201 cells (data not shown) similar to eukaryotic PLCbeta isoforms but unlike PLCgamma and PLCdelta isozymes that are primarily localized in cytosolic fractions (24, 25).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of PLCepsilon in TSA201 cells reveals a PI-PLC. A, Western blot analysis reveals a band of approximately 230 kDa corresponding to Myc-tagged PLCepsilon (arrow) only in cells lysates (50 mg) obtained from TSA201 cells transfected with PLCepsilon , whereas none is found in lysates (50 mg) obtained from TSA201 cells transfected with control (vector). B, membranes (10 mg) isolated from TSA201 cells expressing PLCepsilon (filled circles) exhibit time dependent increases in InsP formation when reconstituted with mixed phospholipid vesicles containing [3H]PIP2 as described under "Experimental Procedures." Data represent the averages ± S.E. of duplicate samples. Similar results were obtained in three independent experiments. Where error bars are not shown, the range was less than the size of the point. MWt., molecular mass.

PLCepsilon has Pl-PLC activity, measured by its ability to hydrolyze exogenous PIP2, a selective substrate of PI-PLCs. As can be seen in Fig. 3B, 10 µg of plasma membranes obtained from PLCepsilon transfected TSA201 cells had a 2-3-fold (61-114 pmol PIP2 hydrolyzed) greater PLC activity over a 15-min incubation period than membranes of cells transfected with control vector (20-46 pmol of PIP2 hydrolyzed).

The Heterotrimeric G Protein Galpha 12 Selectively Stimulates PLCepsilon -mediated Hydrolysis of Polyphosphinositides-- As depicted in the phylogenetic tree (Fig. 1C), the closest mammalian homolog of PLCepsilon is PLCbeta , an effector for heterotrimeric G protein Galpha and beta gamma subunits. Currently, there are no identifiable motifs for proteins that bind to heterotrimeric G proteins. However, truncation of the terminal 112 amino acids of PLCbeta 1 (Gln1030-Leu1142) has been shown to totally abolish regulation of this isoform by Galpha q, suggesting that the C terminus is necessary for Galpha subunit interaction (26). Like PLCbeta , PLCepsilon has a long C terminus, suggesting the possibility for regulation by heterotrimeric G proteins. The ability of eight different constitutively active (GTPase-deficient) mutants of G protein alpha  subunits (Galpha *) to stimulate PLCepsilon activity in TSA201 cells was determined. In the absence of any extracellular activators, co-transfection of Galpha 12* with PLCepsilon augmented PLC activity nearly 3-fold greater than control (Fig. 4A). Cells transfected with Galpha 12* alone did not have increased PLC activity. Co-transfection with Galpha 13* also led to an increase in PLC activity; however, Galpha 13 alone increased endogenous PLC activity, suggesting that the effects obtained with Galpha 13* co-transfected with PLCepsilon were in fact equal in magnitude to the sum of the individual effects of PLCepsilon and Galpha 13* alone. Because co-expression of Galpha 13* with PLCepsilon tended to decrease PLCepsilon expression somewhat, we cannot be sure that Galpha 13* has no effect. In many systems Galpha 12 and Galpha 13 are interchangable, that is they both regulate the same effectors. A clear exception has been described for p115RhoGEF. Although both Galpha 12 and Galpha 13 can bind to this novel RhoGEF (p115RhoGEF serves as a GAP for both Galpha subunits), only Galpha 13 can activate the GEF activity toward Rho (14). Galpha s* and Galpha i* had no effect on PLCepsilon activity. The ability of other Galpha subunits: Galpha i2*, Galpha z*, and Galpha o* to regulate PLCepsilon were also determined; however, none of these Galpha subunits increased PLC activity when co-transfected with PLCepsilon (data not shown). Galpha q* expressed in cells greatly increased basal PLC activity most likely by activation of endogenous PLCbeta found in these cells. Co-transfection of PLCepsilon with Galpha q* did not increase PLC activity above Galpha q* transfected cells, suggesting that this Galpha subunit does not activate PLCepsilon . PLCepsilon activity was obtained under conditions where similar amounts of PLCepsilon and Galpha subunits were expressed (Fig. 4, B and C).



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Overexpression of GTPase-deficient heterotrimeric G protein alpha  subunits stimulates PLCepsilon enzymatic activity. A, PI hydrolysis (InsP formation) is stimulated by co-expression of Galpha 12 with PLCepsilon in TSA201 cells. Each value represents the mean ± S.E. of four experiments each carried out in duplicate. B, protein (100 mg) obtained from cells transfected with either control (vector), Galpha subunits, and PLCalpha alone or in combination with Galpha subunits were separated by SDS-polyacrylamide gel electrophoresis on an 6% gel and transferred unto nitrocellulose. Levels of expression of Galpha subunits were analyzed by Western blotting using antisera directed against Galpha s, Galpha i, Galpha 12, and Galpha 13 as described under "Experimental Procedures." This figure is a representative of four different experiments with similar results. C, protein (100 mg) obtained from cells were separated on a 6% gel and transferred unto nitrocellulose. Levels of expression of PLCepsilon were analyzed using anti-Myc antibody as described under "Experimental Procedures." This figure is a representative of four different experiments with similar results.

PLCepsilon is one of very few known effectors for Galpha 12, because the Galpha 12/Galpha 13 family of heterotrimeric G proteins is currently poorly characterized (27). Galpha 12 and Galpha 13 appear to play an important role in regulating cellular and cytoskeletal changes and may themselves be regulated by the receptors for thrombin and lysophosphatidic acid and other mitogenic agonists (9). Galpha 12 is in fact a highly oncogenic Galpha subunit. A GTPase deficient mutant Galpha 12 Q229L fully transforms NIH 3T3 cells. The transformed cells form foci, grow in semisolid medium, and form tumors in nude mice (28). Galpha 12 has also been found to regulate extracellular signal-regulated kinase and c-Jun kinase pathways (29, 30). It appears that Galpha 12 stimulates c-Jun via activation of Ras; however, the mechanism by which Galpha 12 activates Ras is unknown (31). Perhaps PLCepsilon can act as a direct link between Galpha 12 and Ras.

PLCepsilon Activates Ras and a Downstream Serine/Threonine Kinase MAP Kinase-- The presence of a RasGEF motif in the N terminus of PLCepsilon suggests that PLCepsilon can activate Ras by acting as an exchange factor by promoting the exchange of GTP for bound GDP. Ras mediates its effects on cellular growth and transformation mainly by activating a cascade of serine/threonine kinases including Raf, MEK, and MAP kinase (32). Because MAP kinase (ERK1/2) is a downstream effector of Ras signaling, the ability of PLCepsilon to activate Ras was determined by measuring phosphorylation of MAP kinase. To determine whether PLCepsilon could activate Ras and the MAP kinase pathway independent of PI hydrolysis, the ability of an X domain phosphodiesterase deficient mutant of PLCepsilon was examined. X and Y domains are regions of ~170 and ~260 amino acids, respectively, which share 60% to 40% amino acid identity among all eukaryotic PI-PLCs. The X and Y domains are necessary for phosphodiesterase activity and make up the catalytic core of the enzyme. Bacterial PLCs contain only the X domain. We have previously demonstrated through extensive site-directed mutagenesis of PLC delta 1 that the X domain is responsible for the catalytic hydrolysis of polyphosphoinositides, whereas the Y domain is responsible for substrate binding (33). Mutation of amino acid residues Arg338, Glu341, and His356 in the X domain of PLC delta 1 lead to cleavage defective enzymes (33). These residues are absolutely conserved in all eukaryotic PLCs including PLCepsilon . A cleavage-defective PLCepsilon was created by mutating the conserved histidine at position 1144 to leucine. This residue is analogous to the histidine at position 356 of PLC delta 1. PLCepsilon H1144L is expressed normally as determined by Western blot using anti-Myc antibodies (Fig. 5B) but does not hydrolyze substrate (data not shown). Thus, any effects on Ras mediated by PLCepsilon H1144L would be due to the Ras binding domains of PLCepsilon rather than due to indirect effects of PI hydrolysis and the production of the second messengers DAG and IP3.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   PLCepsilon activates the MAP kinase pathway. A, cell lysates (~3-5 mg of total protein) were acquired from control, PLCepsilon , PLCepsilon H1144L, and RasGRF2 transfected cells, and MAP kinase activity was assayed as described under "Experimental Procedures." The data are the means ± S.E. of two to six experiments using separate transfections. B, Western blot analysis of cell lysates (100 mg), using HA antibody 12CA5 for MAP kinase, anti-Myc for PLCepsilon , or anti-FLAG antibody for RasGF2 as described under "Experimental Procedures." Antibodies were used at a dilution of 1:1000. This figure is a representative of three to five different experiments repeated with similar results.

To determine whether PLCepsilon and PLCepsilon H1144L could indeed activate the MAP kinase pathway, TSA201 cells were co-transfected with either pcDNA3 vector (control), PLCepsilon , PLCepsilon H1144L, or RasGRF2 (as a control for activation of the Ras/MAP kinase pathway) and HA-tagged MAP kinase. Immunoprecipitates obtained from cells expressing PLCepsilon show a 3-fold (454 pmol/min/mg total protein) increase in phosphorylation of MAP kinase relative to control immunoprecipitates (139 pmol/min/mg) obtained from cells transfected with vector alone (Fig. 5A). Expression of PLCepsilon H1144L also stimulates phosphorylation of MAP kinase, indicating that PI hydrolysis is not necessary for activation of the Ras effector MAP kinase. In fact, PI hydrolysis seems to inhibit the activation of MAP kinase, because H1144L-stimulated MAP kinase approximately 2-fold greater than wild type PLCepsilon (907 and 454 pmol/min/mg, respectively). The expression of wild type PLCepsilon and H1144L was nearly identical (31.9 versus 29.3 relative units, respectively) in TSA201 cells, as was the level of HA-MAP kinase. Therefore, levels of expression did not account for the differences in activity (Fig. 5B). The products of PI hydrolysis IP3 and DAG could act as indirect negative regulators of the RasGEF activity and thereby act as a negative feedback loop. For example, stimulation of protein kinase C by DAG might lead to phosphorylation of PLCepsilon and inhibition of the RasGEF activity. The known RasGEF, RasGRF2, gave the most robust stimulation (1231 pmol/min/mg) yet was comparable with the stimulation by H1144L and PLCepsilon , demonstrating that PLCepsilon is a fairly robust activator of MAP kinase.

The role of the Ras-associating or RA domains is presently unknown. Proteins such as RalGDS that contain both Ras-GEF and RA domains are assumed to serve as links between different Ras family members. Although RA domains are known to bind to the effector loop of activated members of the Ras superfamily, the RA domain seems to not be necessary for regulation of GDP/GTP exchange by some proteins. For example, activated Ras stimulates RGL (for RalGDS-like), which exchanges GDP for GTP on Ral in vivo. In vitro, however, the RA domain of RGL is not necessary for GDP/GTP exchange on Ral (34). It is presumed that the role of the RA domain in RGL activation of Ral is to mediate redistribution of RGL to the membranes where Ral is located. To differentiate the role of the RasGEF domain from that of the RA domain of PLCepsilon in stimulating MAP kinase, a Myc-tagged construct PLCepsilon -GEF was made of the N-terminal 600 amino acids of PLCepsilon . This construct contains the entire RasGEF domain but lacks the X and Y phosphodiesterase domains and both of the C-terminal RA domains. PLCepsilon -GEF was able to stimulate MAP kinase to a level comparable with the wild type holo enzyme (Fig. 6), suggesting that the RasGEF domain is sufficient for activation of the Ras/MAP kinase pathway by PLCepsilon and that the C-terminal RA domains are not necessary. This result is consistent with the previously described findings for RGL (34).



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 6.   The GEF domain of PLCepsilon is sufficient to activate MAP kinase. A, cell lysates (~3-5 mg of total protein) were acquired from control, PLCepsilon , PLCepsilon -GEF transfected cells, and MAP kinase activity assayed as described under "Experimental Procedures." The data are the means ± S.E. of three experiments using separate transfections. B, Western blot analysis of cell lysates (100 mg), using HA antibody 12CA5 for MAP kinase, and anti-Myc for PLCepsilon and PLCepsilon -GEF as described under "Experimental Procedures." Antibodies were used at a dilution of 1:1000. This figure is a representative of three different experiments with similar results.

It is difficult to predict the function of the RA domains in PLCepsilon from these studies. They do not seem to be involved with membrane association, because the PLCepsilon -GEF construct is highly targeted to membranes (data not shown). The domains might be closely associated with the phosphodiesterase catalytic domains (X and Y) because when one or more of the RA domains are truncated, the resulting enzyme has very little phosphodiesterase activity, suggesting that these domains are necessary for proper folding of the enzyme (data not shown). This is similar to truncation of the delta 1 isoform of PLC, where deletion of even a few C-terminal residues leads to inactivation of phosphodiesterase activity.3 Because of the potential interaction of the RA domains with the X and Y domains, the ability of activated Ras to regulate the phosphodiesterase activity of PLCepsilon was assessed by co-transfection. As can be seen from Fig. 7A, v-Ras does not stimulate but may inhibit PLCepsilon in vivo. Transfection of cells with PLCepsilon alone increased PI hydrolysis 3.5-fold, whereas co-transfection with PLCepsilon and v-Ras lead to an increase of only 2-fold. Expression levels of v-Ras and PLCepsilon did not vary substantially among different conditions. Actually, PLCepsilon expression was slightly greater when co-transfected with v-Ras. Overall, these results suggest a potential role for PLCepsilon in regulating Ras activation and thus activation of the MAP kinase pathway in a manner dependent upon the RasGEF domain and independent of PI hydrolysis.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Activated Ras inhibits PLCepsilon phosphodiesterase activity in vivo. A, PI hydrolysis (InsP formation) is assayed in whole cells after transfection in TSA201 cells. Each value represents the means ± S.E. of two experiments each carried out in duplicate. B, Western blot demonstrating expression of v-Ras and PLCepsilon . This figure is a representative of two different experiments with similar results.

PLCepsilon Activates Ras-- More direct evidence of the ability of PLCepsilon to activate Ras comes from experiments in which GTP-Ras is trapped using the Ras effector Raf1. The minimal RBD of Raf1 (amino acids 51-131) binds very tightly and specifically to the GTP-bound form of Ras (Kd 20 nM), whereas the affinity for RasGDP is 3 orders of magnitude lower (35). To determine whether PLCepsilon could indeed act as an exchange factor for Ras, TSA201 cells were transiently co-transfected with either pcDNA3 (control), PLCepsilon , PLCepsilon H1144L, or RasGRF2 (as a GEF control for activation of Ras) and Ha-Ras. The cells were harvested after 48 h and RasGTP was identified by precipitation with GST-RBD and immunoblotting using anti-Ras antibody. Fig. 8A demonstrates that GST-RBD bound RasGTP was increased significantly in cells transfected with PLCepsilon , PLCepsilon H1144L, and the known RasGEF, RasGRF2. The fold increase in RasGTP for PLCepsilon , H1144L, and RasGRF was 4.2-, 9.3-, and 4.1-fold, respectively. Although levels of expression for PLCepsilon and the phosphodiesterase deficient mutant H1144L were very similar (Fig. 8B), H1144L was 2.2-fold more potent for activation of Ras. As discussed in the previous section, H1144L was also more potent in activating MAP kinase. The increase in H1144L activity suggests that the phosphodiesterase activity may serve as a negative feedback regulator of the RasGEF activity. Levels of expression for Ha-Ras were similar for each of the experimental conditions (Fig. 8B). There was no appreciable RasGTP detected in control cells. Basal levels of RasGTP were reduced significantly by preincubation of the cells in serum-free medium for 12 h. Taken together, these results provide more direct evidence that PLCepsilon indeed activates Ras by acting as a RasGEF.



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of PLCepsilon and H1144L on Ras activation. A, cells were transfected with either vector (control), PLCepsilon , PLCepsilon H1144L, or RasGRF2 in combination with Ha-Ras. Cell lysates were prepared, and the amount of protein was determined. GTP-Ras was isolated by binding to GST-RBD and visualized by Western blot Analysis as described under "Experimental Procedures." Approximately equal amounts of protein were loaded per lane. This figure is a representative of three to five different experiments with similar results. B, Western blot analysis of cells lysates (100 mg), using anti-Myc, anti-HA, anti-FLAG, or anti-Ras antibodies. Antibodies were used in dilutions of 1:1000.

This work demonstrates that PLCepsilon is a widely expressed unique PLC enzyme that constitutes a new PLC family possessing bifunctional activity, both PLC and RasGEF activity. As such, PLCepsilon may mediate the effects of G protein-coupled receptors, especially those coupled with Galpha 12/Galpha 13 through two divergent pathways involving phosphatidylinositol hydrolysis as well as direct activation of the Ras/MAP kinase pathway. Thus, this new member of the PLC family may play a vital role in transducing signals from the plasma membrane to the nucleus through multiple pathways to modulate cytoskeletal changes, cell growth, and mitogenesis.


    ACKNOWLEDGEMENTS

We thank Tatyana A. Voyno-Yasenetskaya for kindly providing the constitutively active Galpha s*, Galpha i*, Galpha 12*, Galpha 13*, Galpha z*, Galpha o*, and Galpha 16* and David R. Manning for providing antibodies against Galpha s, Galpha 12, and Galpha 13. We also thank Dr. Alan Wolfman and Johannes L. Bos for kindly providing GST-Raf1 minimal Ras-Binding Domain (GST-RBD), Mike Moran for providing RasGRF2, and Mark Marshall for v-Ras G12V and Ha-Ras. We also thank John Campion for technical assistance.


    FOOTNOTES

* This work was supported by a Merit Review Grant from the Department of Veterans Affairs (to J. W. L.), by National Institute of Health Grants HL03836 (to I. L.) and HL55591 and HL03961 (to J. W. L.), by the Robert H. Lurie Comprehensive Cancer Center's American Cancer Society Institutional Research Grant IRG-93-037-06 (to I. L.), and by American Heart Association Grant-in-Aid 9951330Z (to I. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF170071.

|| To whom correspondence should be addressed: Dept. of Pathology and Feinberg Cardiovascular Research Institute, Tarry Bldg. 12-703, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Tel.: 312-503-0450; Fax: 312-503-0137; E-mail: j-lomasney@northwestern.edu.

Published, JBC Papers in Press, October 5, 2000, DOI 10.1074/jbc.M008119200

2 J. W. Lomasney and K. King, submitted for publication.

3 K. King and J. W. Lomasney, personal communication.


    ABBREVIATIONS

The abbreviations used are: PLC, phospholipase C; PI-PLC, PI-PLC; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; MAP, mitogen-activated protein; RasGEF, Ras guanine nucleotide exchange factor; RA, Ras-associating; RBD, Ras-binding domain; PI, phosphatidylinositol; EST, expressed sequence tag; PCR, polymerase chain reaction; HA, hemagglutinin; GST, glutathione S-transferase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES


1. Rhee, S. G., and Bae, Y. S. (1997) J. Biol. Chem. 272, 15045-15048[Free Full Text]
2. Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205[CrossRef][Medline] [Order article via Infotrieve]
3. Rhee, S. G., Suh, P. G., Ryu, S. H., and Lee, S. Y. (1989) Science 244, 546-550[Medline] [Order article via Infotrieve]
4. Lomasney, J. W., Cheng, H. F., Wang, L. P., Kuan, Y. S., Liu, S. M., Fesik, S. W., and King, K. (1996) J. Biol. Chem. 271, 25316-25326[Abstract/Free Full Text]
5. Bromann, P. A., Boetticher, E. E., and Lomasney, J. W. (1997) J. Biol. Chem. 272, 16240-16246[Abstract/Free Full Text]
6. Yagisawa, H., Sakuma, K., Paterson, H. F., Cheung, R., Allen, V., Hirata, H., Watanabe, Y., Hirata, M., Williams, R. L., and Katan, M. (1998) J. Biol. Chem. 273, 417-424[Abstract/Free Full Text]
7. Kim, Y. H., Park, T. J., Lee, Y. H., Baek, K. J., Suh, P. G., Ryu, S. H., and Kim, K. T. (1999) J. Biol. Chem. 274, 26127-26134[Abstract/Free Full Text]
8. Bokoch, G. M. (1996) FASEB J. 10, 1290-1295[Abstract/Free Full Text]
9. Gutkind, J. S. (1998) Oncogene 17, 1331-1342[CrossRef][Medline] [Order article via Infotrieve]
10. Post, G. R., and Brown, J. H. (1996) FASEB J. 10, 741-749[Abstract/Free Full Text]
11. Luttrell, L. M., Della Rocca, G. J., van Biesen, T., Luttrell, D. K., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 4637-4644[Abstract/Free Full Text]
12. van Biesen, T., Hawes, B. E., Raymond, J. R., Luttrell, L. M., Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 1266-1269[Abstract/Free Full Text]
13. Hart, M. J., Jiang, X. J., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., Sternweis, P. C., and Bollag, G. (1998) Science 280, 2112-2114[Abstract/Free Full Text]
14. Kozasa, T., Jiang, X. J., Hart, M. J., Sternweis, P. M., Singer, W. D., Gilman, A. G., Bollag, G., and Sternweis, P. C. (1998) Science 280, 2109-2111[Abstract/Free Full Text]
15. Lopez, I., Arnold, R. S., and Lambeth, J. D. (1998) J. Biol. Chem. 273, 12846-12852[Abstract/Free Full Text]
16. Martin, T. F. (1983) J. Biol. Chem. 258, 14816-14822[Abstract/Free Full Text]
17. Kim, M. J., Min, D. S., Ryu, S. H., and Suh, P. G. (1998) J. Biol. Chem. 273, 3618-3624[Abstract/Free Full Text]
18. Zu, Y. L., Ai, Y., Gilchrist, A., Labadia, M. E., Sha'afi, R. I., and Huang, C. K. (1996) Blood 87, 5287-5296[Abstract/Free Full Text]
19. de Rooij, J., and Bos, J. L. (1997) Oncogene 14, 623-625[CrossRef][Medline] [Order article via Infotrieve]
20. Shibatohge, M., Kariya, K., Liao, Y., Hu, C. D., Watari, Y., Goshima, M., Shima, F., and Kataoka, T. (1998) J. Biol. Chem. 273, 6218-6222[Abstract/Free Full Text]
21. Ponting, C. P., and Benjamin, D. R. (1996) Trends Biochem. Sci. 21, 422-425[CrossRef][Medline] [Order article via Infotrieve]
22. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve]
23. Margolskee, R. F., McHendry-Rinde, B., and Horn, R. (1993) BioTechniques 15, 906-911[Medline] [Order article via Infotrieve]
24. Kim, C. G., Park, D., and Rhee, S. G. (1996) J. Biol. Chem. 271, 21187-21192[Abstract/Free Full Text]
25. Ryu, S. H., Suh, P. G., Cho, K. S., Lee, K. Y., and Rhee, S. G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 6649-6653[Abstract]
26. Wu, D., Jiang, H., Katz, A., and Simon, M. I. (1993) J. Biol. Chem. 268, 3704-3709[Abstract/Free Full Text]
27. Strathmann, M. P., and Simon, M. I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5582-5586[Abstract]
28. Xu, N., Bradley, L., Ambdukar, I., and Gutkind, J. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6741-6745[Abstract]
29. Voyno-Yasenetskaya, T. A., Faure, M. P., Ahn, N. G., and Bourne, H. R. (1996) J. Biol. Chem. 271, 21081-21087[Abstract/Free Full Text]
30. Collins, L. R., Minden, A., Karin, M., and Brown, J. H. (1996) J. Biol. Chem. 271, 17349-17353[Abstract/Free Full Text]
31. Wadsworth, S. J., Gebauer, G., van Rossum, G. D., and Dhanasekaran, N. (1997) J. Biol. Chem. 272, 28829-28832[Abstract/Free Full Text]
32. Lowy, D. R., and Willumsen, B. M. (1993) Annu. Rev. Biochem. 62, 851-891[CrossRef][Medline] [Order article via Infotrieve]
33. Cheng, H., Jiang, M., Chen, C., Liu, S., Wong, L., Lomasney, J. W., and King, K. (1995) J. Biol. Chem. 270, 1-11[Free Full Text]
34. Murai, H., Ikeda, M., Kishida, S., Ishida, O., Okazaki-Kishida, M., Matsuura, Y., and Kikuchi, A. (1997) J. Biol. Chem. 272, 10483-10490[Abstract/Free Full Text]
35. Herrmann, C., Martin, G. A., and Wittinghofer, A. (1995) J. Biol. Chem. 270, 2901-2905[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.